Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01377389 · ClinicalTrials.gov registry record · Phase 2
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01377389: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01377389 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01377389, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if ipilimumab in combination with either Lupron® (leuprolide), Zoladex® (goserelin), or Firmagon® (degarelix) can affect prostate-specific antigen (PSA) levels in patients with prostate cancer. Researchers also want to learn if these drug combinations affect the body's immune system. The safety of these drug combinations will also be studied.
Interventions
- DRUG Ipilimumab
- DRUG Goserelin
- DRUG Degarelix
- DRUG Leuprolide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-06-17 |
| Est. Completion | 2017-04-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01377389
The ClinicalTrials.gov registry entry for NCT01377389 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ipilimumab is the first listed.
NCT01377389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01377389 about?
NCT01377389 is a clinical study titled "Ipilimumab + Androgen Depravation Therapy in Prostate Cancer". The goal of this clinical research study is to learn if ipilimumab in combination with either Lupron® (leuprolide), Zoladex® (goserelin), or Firmagon® (degarelix) can affect prostate-specific antigen (PSA) levels in patients with prostate cancer. Researchers also want to learn if these drug combinat...
What is the current status of trial NCT01377389?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2011-06-17. Estimated completion is 2017-04-07.
What interventions are being tested in trial NCT01377389?
The interventions under investigation include: Ipilimumab (DRUG), Goserelin (DRUG), Degarelix (DRUG), Leuprolide (DRUG).
Who is sponsoring clinical trial NCT01377389?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.